Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | WEE1 | P30291 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25420071 | 0.83 | TTR (0.42) | ESR1ESR2MAOAUGT1A1MAOB | |
| SCHEMBL5948946 | 0.83 | ESR1 (0.52) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL5948451 | 0.80 | ESR1 (0.48) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL25422634 | 0.80 | TTR (0.40) | ESR1ESR2MAOAUGT1A1MAOB | |
| SCHEMBL25421166 | 0.78 | TTR (0.41) | ESR1ESR2MAOAUGT1A1MAOB | |
| SCHEMBL25419103 | 0.77 | TAAR1 (0.34) | ESR1ESR2 | |
| SCHEMBL5949079 | 0.77 | TAAR1 (0.34) | ESR1ESR2 | |
| SCHEMBL25422120 | 0.75 | TTR (0.42) | ESR1ESR2MAOAUGT1A1MAOB | |
| SCHEMBL29001442 | 0.74 | ALDH1A1 (0.42) | ESR1ESR2MAOAUGT1A1MAOB | |
| SCHEMBL30310822 | 0.74 | ALDH1A1 (0.42) | ESR1ESR2MAOAUGT1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034173-B2 | Chemical products suited for use as co-catalysts, method for the preparation thereof and their use in catalyst systems for producing polyolefins | BASELL POLYOLEFINE GMBH (DE) | 2006-04-25 | — | — | US | disclosed |
| US-20030144434-A1 | Chemical products suited for use as co-catalysts, method for the preparation thereof and their use in catalyst systems for producing polyolefins | EQUISTAR CHEMICALS, LP | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144434-A1 | Chemical products suited for use as co-catalysts, method for the preparation thereof and their use in catalyst systems for producing polyolefins | CBR1, COX6C, CBR3 | ESR1 4091/4885ESR2 2428/4885KDM1A 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.